MX2024009177A - Compuestos y metodos de uso - Google Patents
Compuestos y metodos de usoInfo
- Publication number
- MX2024009177A MX2024009177A MX2024009177A MX2024009177A MX2024009177A MX 2024009177 A MX2024009177 A MX 2024009177A MX 2024009177 A MX2024009177 A MX 2024009177A MX 2024009177 A MX2024009177 A MX 2024009177A MX 2024009177 A MX2024009177 A MX 2024009177A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- compounds
- methods
- formula
- ring
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263303409P | 2022-01-26 | 2022-01-26 | |
| US202263435210P | 2022-12-23 | 2022-12-23 | |
| PCT/US2023/011654 WO2023146987A1 (en) | 2022-01-26 | 2023-01-26 | Compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009177A true MX2024009177A (es) | 2024-11-08 |
Family
ID=85328599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009177A MX2024009177A (es) | 2022-01-26 | 2024-07-24 | Compuestos y metodos de uso |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250136594A1 (https=) |
| EP (1) | EP4469438A1 (https=) |
| JP (1) | JP2025503969A (https=) |
| KR (1) | KR20240153335A (https=) |
| AU (1) | AU2023213736A1 (https=) |
| CA (1) | CA3243127A1 (https=) |
| IL (1) | IL314320A (https=) |
| MX (1) | MX2024009177A (https=) |
| TW (1) | TW202339736A (https=) |
| WO (1) | WO2023146987A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025525104A (ja) * | 2022-07-28 | 2025-08-01 | ベイジン アースワイズ テクノロジー カンパニー リミテッド | Ｐｒｍｔ５阻害剤 |
| WO2024104244A1 (zh) * | 2022-11-15 | 2024-05-23 | 四川科伦博泰生物医药股份有限公司 | 草酸酰胺化合物、包含其的药物组合物及其制备方法和用途 |
| CN120019044A (zh) * | 2022-12-22 | 2025-05-16 | 成都苑东生物制药股份有限公司 | 一种取代草酰胺类衍生物、其制备方法及用途 |
| JP2026504087A (ja) * | 2023-01-17 | 2026-02-03 | スジョウ・プヘ・バイオファーマ・カンパニー・リミテッド | Ｐｒｍｔ５－ｍｔａ阻害剤 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN118290386B (zh) * | 2024-04-02 | 2025-06-20 | 国科大杭州高等研究院 | 7-羟基黄酮类化合物及其制备方法和应用 |
| WO2025217297A1 (en) | 2024-04-09 | 2025-10-16 | Tango Therapeutics, Inc. | Prmt5 inhibitors for use in methods of treating mta-accumulating cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US11077101B1 (en) * | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2021004547A1 (en) * | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
| CN116568677A (zh) * | 2020-07-31 | 2023-08-08 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
-
2023
- 2023-01-26 JP JP2024544444A patent/JP2025503969A/ja active Pending
- 2023-01-26 KR KR1020247028555A patent/KR20240153335A/ko active Pending
- 2023-01-26 IL IL314320A patent/IL314320A/en unknown
- 2023-01-26 US US18/833,315 patent/US20250136594A1/en active Pending
- 2023-01-26 WO PCT/US2023/011654 patent/WO2023146987A1/en not_active Ceased
- 2023-01-26 CA CA3243127A patent/CA3243127A1/en active Pending
- 2023-01-26 AU AU2023213736A patent/AU2023213736A1/en active Pending
- 2023-01-26 EP EP23706923.2A patent/EP4469438A1/en active Pending
- 2023-01-30 TW TW112103169A patent/TW202339736A/zh unknown
-
2024
- 2024-07-24 MX MX2024009177A patent/MX2024009177A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023146987A1 (en) | 2023-08-03 |
| JP2025503969A (ja) | 2025-02-06 |
| AU2023213736A1 (en) | 2024-08-01 |
| KR20240153335A (ko) | 2024-10-22 |
| IL314320A (en) | 2024-09-01 |
| EP4469438A1 (en) | 2024-12-04 |
| CA3243127A1 (en) | 2023-08-03 |
| US20250136594A1 (en) | 2025-05-01 |
| TW202339736A (zh) | 2023-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009177A (es) | Compuestos y metodos de uso | |
| MX2025000642A (es) | Compuestos macrociclicos para el tratamiento de cancer | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| PH12021553107A1 (en) | Benzisoxazole sulfonamide derivatives | |
| MX2025001619A (es) | Inhibidor de pde4b y uso del mismo | |
| MX2024015459A (es) | Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico | |
| MX2023001379A (es) | Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a. | |
| WO2021055728A8 (en) | Small molecule inhibitors of kras g12c mutant | |
| MX2025008327A (es) | Composiciones y metodos para el tratamiento de trastornos del snc | |
| WO2022115381A8 (en) | Compositions and methods for treating cns disorders | |
| GEP20267861B (en) | Anti-viral compounds | |
| MX2024009540A (es) | Esteroides neuroactivos y composiciones de estos. | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| MX2023010909A (es) | Derivados de purina como agentes anticancerigenos. | |
| EP1467970A4 (en) | HYDROXYNAPHTHYRIDINONCARBOXYL ACID AMIDES SUFFICIENT AS INHIBITORS OF THE HIV INTEGRASE | |
| MX2024003738A (es) | Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico. | |
| ZA202401684B (en) | Novel parp7 inhibitor and use thereof | |
| MX2023015139A (es) | Inhibidores de mutacion de her2. | |
| MX2021011286A (es) | Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia. | |
| ZA202501471B (en) | Preparation and use of quinazolinone derivative as kinase inhibitor | |
| MX2025010952A (es) | Derivados de amida para inhibir el gen nlrp3 y usos de los mismos | |
| MXPA05005790A (es) | Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central. | |
| CR20230218A (es) | Nuevos derivados de indazol acetileno | |
| MX2023009166A (es) | Derivados de quinoxalina y sus usos. | |
| MXPA04005157A (es) | Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal. |